Eupraxia Pharmaceuticals ... (EPRX)

NasdaqCM: EPRX · Real-Time Price · USD

6.67

+0.19 (2.93%)

At close: Aug 13, 2026, 3:59 PM

6.93

+3.90%

After-hours: 7:38 PM

2.93% (1D)

Bid	6.65
Market Cap	435.73M
Revenue (ttm)	n/a
Net Income (ttm)	-46.98M
Beta	1.50
EPS (ttm)	-1.08
PE Ratio (ttm)	n/a
Forward PE	-6.41
P/B (ttm)	6.62
P/S (ttm)	n/a
Earnings Date	Nov 3, 2026

Ask	6.69
Volume	250,494
Avg. Volume (20D)	363,675
Open	6.70
Previous Close	6.48
Day's Range	6.50 - 6.87
52-Week Range	5.04 - 9.32
Analyst	Strong Buy
Price Target	15.75 (136.13%)
Dividends	n/a
Ex-Dividend Date	n/a

About EPRX

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical ...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 5, 2024

Employees 49

Stock Exchange NasdaqCM

Ticker Symbol EPRX

Website https://www.eupraxiapharma.com

Full Company Profile

Financial Performance

In 2025, Eupraxia Pharmaceuticals's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -38.58M, an increase of 51.26%.

Financial Statements

Analyst Forecast

According to 10 analyst ratings, the average rating for EPRX stock is "Strong Buy". The 12-month stock price forecast is 15.75, which is upside of 136.13% from the latest price.

Stock Forecasts

Earnings Surprise

Eupraxia Pharmaceuticals has released their quarterly earnings on Aug 11, 2026:

Revenue of $0 misses estimates by $0, with NaN% YoY growth.

EPS of -0.23 misses estimates by 0.00, with -9.52% YoY decline.

Next Earnings Release

Eupraxia Pharmaceuticals Inc. is scheduled to release its earnings on Nov 3, 2026, during market hours.
Analysts project revenue of ... Upgrade

News

3 days ago · Zacks

Wall Street Analysts See a 145.35% Upside in Eupraxia Pharmaceuticals Inc. (EPRX): Can the Stock Really Move This High?

The consensus price target hints at a 145.4% upside potential for Eupraxia Pharmaceuticals Inc. (EPRX). While empirical research shows that this sought-after metric is hardly effective, an upward tren...